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Untreated infection with the human immunodeficiency virus (HIV) 
leads to severe physical debilitation, culminating in the acquired 
immune deficiency syndrome (AIDS).  Multiple infections, 
body mass loss, physical weakness and wasting are characteristic 
manifestations of each of the four stages of HIV/AIDS, respectively 
(Table I). The latter two impact especially on the affected person’s 
ability to function, as well as on social and economic levels. 
However, even though antiretroviral treatment (ART) is now 
available at many selected public clinics in South Africa, it only 
complicates the issues surrounding body composition and physical 
function. 
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The information gained could 
lead the medical practitioner 
to recommend lifestyle 
changes, including exercise, 
which will further benefit the 
patient over and above the 
use of ART.
Table I.  The WHO classification system for HIV infection (rewritten from Weatherall DJ, Ledingham JGG,  
Warrell DA. Oxford Textbook of Medicine. 3rd ed.Oxford, UK: Oxford University Press, 1996)
Group A - C based on laboratory variables
Lymphocyte count (x106/l) CD4+ count (x106/l)
A >2 000 >500
B 1 000 - 2 000 200 - 500
C <1 000 <200
Group 1 - 4 based on clinical variables
Clinical group 1 HIV infected: Asymptomatic or with only persistent generalised lymphadenopathy  
Exercise: Can participate in normal physical activities  
Clinical group 2 Early-stage disease: Symptomatic with body mass loss of <10%  
Symptoms: recurrent upper respiratory tract infections and herpes zoster (shingles) infection occurring within 5 
years
Exercise: Can still maintain normal physical activity 
Clinical group 3 Intermediate-stage disease: Body mass loss >10%, unexplained chronic diarrhoea for >1 month, unexplained 
prolonged fever for >1 month, oral candidiasis, oral hairy leukoplakia, pulmonary tuberculosis within previous 12 
months, severe bacterial infections 
Physical ability: Frequently bedridden, but <50% of the day/s during the previous month  
Clinical group 4 Late stage disease: Diagnosed with any of the AIDS-defining illnesses 
Physical ability: Bedridden >50% of the day/s during the previous month  
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AIDS-related wasting and ART-related 
lipodystrophy are physical conditions 
affecting the patient and can be monitored 
on a regular basis. The physical assessments 
should be practical, i.e. cost and time 
efficient, objective, accurate and relevant. 
With proper training, determination of 
body composition using anthropometry 
(measurement of skinfold thickness and 
various circumference measurements) fulfils 
these criteria. The information gained could 
lead the medical practitioner to recommend 
lifestyle changes, including exercise, which 
will further benefit the patient over and 
above the use of ART.
Finally, according to UNAIDS and the 
WHO, 57% of people living with HIV in 
sub-Saharan Africa are women.  Therefore, 
this review focuses (where possible) on the 
physical effects of HIV on infected women 
and the impact of ART on this population. 
The AIDS wasting 
syndrome (AWS)
Wasting is directly associated with HIV/
AIDS disease progression. A body mass loss 
greater than 10% before AIDS is associated 
with an increased risk of death.1  Even a 
body mass loss of between 5% and 10% 
has been associated with an increased risk 
of opportunistic complications. However, 
although measurement of body mass is 
practical, it may be too insensitive, as patients 
with a small body mass loss may actually be 
losing a greater amount of essential lean 
body mass (LBM).  
•    Melchior et al.2 found that LBM 
index (LBM (kg)/height2 (m2)) was an 
independent predictor of survival in 
patients with HIV/AIDS, irrespective of 
body mass.  
•    Interventions that restore muscle mass 
are therefore critical for patients suffering 
from the wasting syndrome, or for those 
who suffered from it before being on 
ART.
A drawback of many published studies 
on HIV/AIDS is that most of the study 
participants were men. In contrast to men, 
women lose proportionately more fat during 
HIV infection;3,4 therefore, in comparison, 
they preserve more lean tissue.  A higher 
initial body fat content may predispose 
women to lose relatively more fat than LBM 
during wasting.  However, conclusions drawn 
from women living in a Western society 
will not necessarily reflect those found in 
sub-Saharan Africa where socio-economic 
factors and ethnicity could influence body 
composition changes. Mechanisms of wasting in patients 
with HIV/AIDS
There are often multiple underlying causes 
of the wasting process. Opportunistic 
infections, chronic diarrhoea, decreased 
dietary energy intake and increased resting 
energy expenditure (hypermetabolism) are 
correlated with body mass loss.2  Primary 
Table II.  Antiretroviral medications and side-effects that could impact 
on body composition and willingness or ability to exercise (adapted from 
Baylor College of Medicine, 2003. HIV curriculum for the health  
professional (www.bcm.edu))✳
Class Antiretroviral drug Possible side-effects
Didanosine (ddI) (Videx) Common: nausea, vomiting, diarrhoea
Severe: peripheral neuropathy, electrolyte ab-
normalities, lactic acidosis 
Lamivudine (3TC)(Epivir) Common: nausea, diarrhoea, headache, fatigue 
Severe: lactic acidosis 
Zalcitabine (ddC) (Hivid) Common: headache, malaise
Severe: peripheral neuropathy, haematological 
toxicity 
Zidovudine (AZT)  
(Retrovir; Zidovir)
Common: haematological toxicity, headache
Less common: myopathy, myositis 
Stavudine (d4T) (Stavir; 
Zerit)
Common: headache, nausea, vomiting,  
diarrhoea
Severe: peripheral neuropathy, lactic acidosis 
Abacavir (in Trizivar; 
Ziagen)
Common: nausea, vomiting, diarrhoea, loss of 
appetite, malaise, headache
Tenofovir (Disoproxil, 
Fumarate, Viread)
Common: headache, nausea, lactic acidosis
Zidovudine/lamivudine 
(Combivir or Duovir; in 
Trizivar)
Common: lactic acidosis 
Delavirdine (Rescriptor) Common: headache, fatigue, nausea, vomiting, 
diarrhoea
Nevirapine (Nevimune; 
Viramune)
Common: sedative effects, headache, nausea, 
diarrhoea
Efavirenz (Stocrin) Common: central nervous system (dizziness, 
etc.)
Indinavir (Crixivan) Common: nausea, headache,  
hyperbilirubinaemia
Less common: hyperglycaemia
Nelfinavir (Viracept) Common: nausea, vomiting, diarrhoea,  
headache 
Less common: abdominal pain, hyperglycaemia
Saquinavir (Invi-Rase)
 
Common: nausea, vomiting, diarrhoea,  
headache
Less common: hyperglycaemia
Saquinavir (Fortovase) Common:  nausea, vomiting, diarrhoea,  
headache
Less common: hyperglycaemia
Ritonavir (Norvir) Common: nausea, vomiting, diarrhoea,  
anorexia
Less common: increased serum triglyceride and 
cholesterol, hyperglycaemia
Lopinavir/ritonavir  
(Kaletra)
Common: nausea, vomiting, diarrhoea,  
headache
Less common: hyperglycaemia 
Amprenavir (Agenerase) Common: headache, nausea, vomiting,  
diarrhoea
✳ Some of the abovementioned trade names are used internationally and are included for reference when accessing 
international literature.
NRTI
NNRTI
PI
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muscle disease has been implicated as 
another possible underlying mechanism of 
the wasting syndrome.5,6 
•    Hypermetabolism is related to endocrine 
abnormalities or elevated cytokines, or 
both: 
  •    HIV-positive patients may have elevated 
resting cortisol concentrations (which 
can lead to increased tissue catabolism) 
and decreased dihydro-epiandrosterone 
sulphate (DHEAS)(which is anti-
catabolic).7  
  •    Cytokines cause anorexia (cachexia in 
extreme cases), but also stimulate muscle 
proteolysis by activating the ubiquitin-
proteosome pathway.5
•    Deltoid muscle biopsy samples of 30 
patients (of whom 26 were male) with 
the wasting syndrome, revealed that 11 
patients had HIV-related myopathy.6  
The lipodystrophy 
syndrome
Currently, there are three classes of 
ART medications: nucleoside reverse 
transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors 
(NNRTIs) and protease inhibitors (PIs). 
Many of the typical side-effects can affect 
functional capacity (Table II).  In general, 
in South Africa, stavudine, lamivudine 
and efavirenz (Stocrin) are used as the 
first line of treatment, whereas didanosine, 
zidovudine and lamivudine/zidovudine 
(Combivir) are used in cases of treatment 
failure (insufficient viral suppression despite 
compliance) or if there are other reasons to 
alter treatment (e.g. lactic acidosis).  
Disturbances in lipid metabolism leading 
to lipodystrophy, hyperlipidaemia, insulin 
resistance and hyperglycaemia are strongly 
associated with PI-based ART.8,9  However, 
PI-naïve patients treated with two NRTIs 
have also been shown to exhibit the same 
manifestations.10 Even though ART can 
reduce generalised body mass loss and 
improve longevity, the impact on  body 
composition may be negative,8,9 e.g.:  
•    fat loss in the face, arms and legs  
•    increased waist circumference due to 
deposition of intra-abdominal visceral 
fat  
•    accumulation of adipose tissue in areas 
such as the dorso-cervical region of the 
neck and  breasts, sometimes in the form 
of unencapsulated lipomas.  
Lipodystrophy is an adverse effect of ART, 
and not limited to a specific drug or class of 
drugs.
These ART-associated features (Table 
III) resemble some characteristics of the 
metabolic syndrome, and therefore can 
be aggravated by high fat intake, chronic 
psychological stressors and low physical 
activity, leading to further complications 
such as fatty liver, hypertension, 
endothelial dysfunction, renal dysfunction, 
inflammation, hyper-coagulability and 
atherosclerosis.11 
•    The defining physical features of the 
metabolic syndrome  are: body mass index 
(BMI) >30 kg/m2, waist circumference 
>102 cm (men) or >89 cm (women), or a 
waist-to-hip ratio >0.90 (men) and >0.85 
(women).
•    Endurance exercise is frequently 
promoted as a lifestyle intervention for 
the metabolic syndrome and should also 
be implemented in HIV-positive persons 
on ART. 
As fat deposited in the intra-abdominal 
area could be a result of redistribution of 
existing fat12,13 or the preferential deposition 
of ‘new’ fat, it is important to monitor not 
only a global percentage of  body fat but also 
regional distribution. 
Monitoring body 
composition changes
Portable methods for assessing body 
composition include bio-electrical 
impedance analysis (BIA) and skinfold 
measurements. Different equations used with 
BIA resulted in highly variable estimations 
of fat-free mass (FFM) and fat mass (FM) in 
HIV-infected individuals showing signs of 
AIDS wasting,14 and may not be the method 
of choice for this population.  To improve 
the reliability of skinfold measurements, 
the same technician should perform 
measurements repeated on the same 
patients. Measurement of circumferences at 
specific sites is also simple to perform and 
is reliable, provided the specific landmarks 
are understood.  Table IV summarises 
Disturbances in 
lipid metabolism 
leading to 
lipodystrophy, 
hyperlipidaemia, 
insulin 
resistance and 
hyperglycaemia 
are strongly 
associated with 
PI-based ART.
Table III. Clinical aspects of the lipodystrophy syndrome 
Fat accumulation
•   Abdominal obesity
•   Dorsocervical pad (‘buffalo hump’)
•   Cervical hypertrophy
•   Lipomas
•   Breast enlargement
Fat loss
•    Face wasting (reduction or absence of subcutaneous tissue on the cheeks with 
sparing of the facial musculature)
•   Loss of subcutaneous fat of extremities
•   Loss of gluteal mass
Biological abnormalities
•   Glucose intolerance, diabetes, hyperinsulinaemia and increased insulin resistance
•   Hypertriglyceridaemia
•   Hypercholesterolaemia: increased LDL cholesterol, decreased HDL cholesterol
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anthropometric variables related to wasting 
or lipodystrophy.
The only variable in traditional 
anthropometry related to lipodystrophy 
is the waist-to-hip ratio, but it does not 
distinguish between subcutaneous and intra-
abdominal fat.  It is also affected by gluteal 
wasting12 that would exacerbate an already 
abnormal waist-to-hip ratio.  However, the 
female body tends to store fat more easily in 
the gluteal area, which could mask gluteal 
wasting in women.  
A longitudinal study conducted by Galli 
et al.15 found simultaneous fat loss and 
fat accumulation in HIV-positive women 
on ART followed up for 12 months, with 
further progression (especially peripheral 
lipoatrophy) after 24 months.  It is also 
possible for lipoatrophy to occur without 
the concomitant increase in waist 
circumference.16 Of 14 patients with a 
clinically abnormal reduction or an absence 
of subcutaneous fat in the cheeks, 6 did not 
have an enlarged abdomen, while 5 had 
abnormally reduced fat in the legs and arms 
without an enlarged abdomen.  
Exercise – effec tive 
intervention to reduce 
wasting and lipodystrophy
Oral nutritional supplementation combined 
with dietary counselling can diminish whole-
body protein catabolism and increase LBM 
in HIV-positive patients with modest-to-
moderate malnutrition.  Although positive 
effects of whey protein supplementation 
on body mass were found, Agin et al.17 
also showed that the combination of 
supplementation and resistance exercise led 
to gains in LBM, whereas supplementation 
alone increased fat mass.
•    Resistance training is an effective treat-
ment to increase LBM, strength and 
functional status in patients with HIV/
AIDS.18 
•    Progressive resistance training with an 
aerobic component, undertaken for 16 
weeks, reduced trunk fat mass in patients 
on ART.19  
•    Increased LBM lasted up to 8 weeks after 
a resistance training programme was 
discontinued.20    
Grinspoon et al.21 showed that androgen 
administration increases LBM and quality of 
life (QoL), but testosterone administration 
in combination with resistance exercise 
resulted in similar increases in skeletal 
muscle fibre size compared with testosterone 
alone, suggesting  exercise was not essential. 
However, Bhasin et al.,22 who also found 
that testosterone and exercise together did 
not produce greater gains than testosterone 
alone, showed that exercise alone was 
sufficient. 
•    Considering longer-term side-effects of 
androgen treatment, exercise alone may 
be a better long-term strategy to prevent 
or reverse muscle loss in HIV-infected 
persons.
Shevitz et al.23 compared the effectiveness of 
nutritional intervention alone, nutrition with 
oral androgen (oxandrolone), and nutrition 
with progressive resistance training.  The 
mid-thigh muscle cross-sectional area 
increased significantly only when nutrition 
was administered with oxandrolone or with 
resistance training, indicating that nutrition 
alone is not sufficient.  
•    Self-reported physical functioning 
improved significantly with resistance 
training. 
•    QoL improved more with exercise than 
with nutrition or nutrition plus androgen 
interventions. 
•    Exercise is more cost effective.  
Although strength training and cardio-
vascular exercise have been suggested as 
treatment interventions for the AWS, and 
more recently to address the metabolic 
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Table IV.  Anthropometric variables that can be considered as indicators 
of wasting status or manifestations of lipodystrophy, or both
Variables related to
Wasting Lipodystrophy
Body mass (BM) Waist-to-hip ratio (W:H)
Percentage of ideal body mass (%IBW)
Body mass index (BMI)
Percentage of ideal arm circumference (%IAC)
Upper arm fat area (UAFA)* Upper arm fat area (UAFA)
Upper arm muscle area (UAMA)*
Thigh skinfold
Thigh circumference
Fat mass index (FMI)
Lean body mass (LBM)
Fat-free mass index  or LBM index (LBMI)
* Anthropometry calculations for measurements in mm:
   UAMA=[{upper arm circumference - (π x triceps skinfold)}2] / 4π
   UAFA=[π/4 x (upper arm circumference/ π)2] - UAMA
Resistance training 
is an effective 
treatment to 
increase LBM, 
strength and 
functional status in 
patients with  
HIV/AIDS.
Relatively 
straightforward 
lifestyle changes 
(such as eating 
well, exercising 
and adequate 
sleep) can make 
a difference, even 
in a complicated 
context involving 
HIV,  poverty  
and oppression.
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abnormalities associated with ART,19,24 
there is a distinct lack of data on the 
longitudinal effects of cardiovascular 
exercise although it has been shown to be 
safe.25,26  
Quality of life
The number and severity of HIV-related 
symptoms are associated with a patient’s 
perceived QoL.27 QoL includes multiple 
aspects of life satisfaction related to 
physical functioning, mental health status 
and functioning within social roles.28 
Physical functioning includes variables 
such as self-care, mobility and fatigue.
The MOS-HIV questionnaire (HIV-
specific scales adapted from the Medical 
Outcomes Survey) is a widely used 
instrument to assess QoL. An European 
questionnaire (EQ-5D) has been used 
extensively in various countries (including 
Japan, Canada and Zimbabwe), and has 
been translated into Xhosa and validated 
in a South African population.  
Health-promoting behaviours, including 
exercise, improved mental health, 
physical functioning and overall QoL in 
women with HIV who had various socio-
economic and educational stratifications.28 
The researchers concluded that relatively 
straightforward lifestyle changes (such 
as eating well, exercising and adequate 
sleep) can make a difference, even in 
a complicated context involving HIV, 
poverty and oppression.  Resistance 
training and cycling have also been shown 
to increase QoL and physical functioning 
in HIV-infected men and women.19,26,29  
Muscle wasting and impaired QoL 
in a pilot study of 8 women with 
HIV in a South African semi-rural 
clinic
Just before initiating ART, the percentage 
of ideal body mass (%IBW) of the patients 
ranged from 67 to 153. Therefore, it should 
be noted that many infected individuals 
have an initial body mass much greater 
than 100%. Nonetheless, the upper 
arm showed signs of wasting of both 
muscle and fat (low percentage ideal arm 
circumference (%IAC)) despite the fact 
that mean %IBW was normal (Table V). 
Such individuals could be experiencing 
the wasting syndrome (loss of LBM and 
regional loss of fat mass) without having a 
body mass less than 10% of the ideal.  For 
example, one participant was classified 
with late-stage (WHO stage 4) disease 
and her calculated upper arm muscle area 
(UAMA) was below the 5th percentile 
threshold, but her body mass was only 1% 
below the ideal prescribed for a female of 
her height, suggesting muscle wasting but 
not fat wasting.  
Fig. 1 shows the proportion of these 
women who reported no problems, some 
problems or severe problems for each of 
the five QoL dimensions (before ART). 
Patients had difficulties with mobility and 
usual activities. 
Conclusions
There is a complex interaction between 
disease and treatment, and body 
composition, physical activity and QoL 
in patients with HIV/AIDS. Monitoring 
of body mass alone is insufficient to 
understand the dynamic of the patient. 
Insufficient data are available, particularly 
in women, but normal body mass and 
fat deposition in the hip area may mask 
muscle and fat atrophy in other peripheral 
sites. The role of exercise in the long-term 
management strategy is essential for the 
health and QoL of patients before ART 
and for those on ART in order to reverse 
wasting and ameliorate lipodystrophy 
and the accompanying metabolic 
abnormalities.  
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Table V. South African HIV-positive women: Pilot study of  
measurements taken just before initiation of ART
       Baseline pre-ART
Variable Mean±SD N
CD4+ count (cells/μl) 118±67 7
CDC immune category 3±0 7
Body mass (kg) 56.1±14.6 8
Body mass index (kg/m2) 22.4±6.4 7
Percentage of ideal body mass (%) 108±33 7
Arm circumference (cm) 24.7±5.3 8
Waist circumference (cm) 72.0±7.8 8
Percentage of ideal arm circumference (%) 87±17 8
Hip circumference (cm) 94.5±14.4 8
Waist-to-hip ratio 0.77±0.08 8
Fig. 1.  The proportion of HIV-positive women (N=8, just before initiating ART) who fitted into 
one of three categories for variables describing quality of life (QoL).
Fig. 1. The proportion of HIV-positive women (N=8, just before initiating ART) who fitted into
one of three categories for variables describing quality of life (QoL).
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HIV/AIDS and exercise
In a nutshell 
•    AIDS-related wasting and ART-re-
lated lipodystrophy are physical con-
ditions that should be monitored on 
a regular basis.
•    Body mass loss between 5% and 10% 
has been associated with an increased 
risk of opportunistic complications. 
•    Patients with only a small body mass 
loss may actually be losing a greater 
amount of essential lean body mass 
(LBM).
•    Cytokines play a role by causing an-
orexia (cachexia in extreme cases), 
but also stimulate muscle proteolysis 
by activating the ubiquitin-proteo-
some pathway.
•    One-third of patients may have HIV-
related myopathy.
•    Currently lipodystrophy is an adverse 
effect of ART, not limited to a spe-
cific drug or class of drugs, but more 
commonly associated with protease 
inhibitors.
•    Intra-abdominal fat deposition and 
loss of facial and peripheral fat are 
features of lipodystrophy. 
•    Assessment of skinfold thickness and 
circumferences is cost effective, but 
requires proper training for reliable 
measurements.
•    Lipodystrophy shares many features 
with the metabolic syndrome, for 
which endurance exercise is known 
to be beneficial.
•    Interventions that restore muscle 
mass are critical for patients suffer-
ing from the wasting syndrome, or 
for those who suffered from it before 
being on ART. Endurance exercise is 
important for patients on ART. 
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